高敏C反应蛋白可预测动脉瘤性蛛网膜下腔出血后急性肾损伤
结果显示17例(10.4%)发生急性肾损伤,入院时血清高敏C反应蛋白水平与急性肾损伤独立相关(OR=1.2,95%CI 1.1-1.3,P=0.003),高敏C反应蛋白>6.6 mg/L者急性肾损伤发生率显著更高。
要点
- 入院高敏C反应蛋白升高与动脉瘤性蛛网膜下腔出血后急性肾损伤独立相关。
- 高敏C反应蛋白预测急性肾损伤的敏感性76.5%、特异性64.6%。
- 高敏C反应蛋白>6.6 mg/L者急性肾损伤发生率显著更高(P=0.001)。
核心结论
- 血清高敏C反应蛋白水平可能有助于预测动脉瘤性蛛网膜下腔出血患者急性肾损伤的发生。
- 本队列中急性肾损伤患者 delayed cerebral ischemia 发生率和死亡率 tended to be higher,但差异无统计学意义。
研究设计与样本
- 急性肾损伤采用改良KDIGO标准诊断。
- 分析入院时血清高敏C反应蛋白水平与急性肾损伤发生的关系。
主要发现
- 17例(10.4%)患者发生急性肾损伤。
- 急性肾损伤组高敏C反应蛋白水平显著高于非急性肾损伤组。
- 急性肾损伤组死亡率 tended to be higher,但差异无统计学意义(4/17(23.5%) vs. 13/147(8.8%),P=0.081)。
- 多因素分析显示高敏C反应蛋白(OR=1.2,95%CI 1.1-1.3,P=0.003)和抗生素治疗(OR=5.8,95%CI 1.6-20.7,P=0.007)均为急性肾损伤的独立相关因素。
- ROC曲线分析显示高敏C反应蛋白预测急性肾损伤的敏感性76.5%、特异性64.6%。
关键数值与推荐
- 急性肾损伤诊断采用改良KDIGO标准。
- 多因素分析调整了世界神经外科医师联盟分级、糖尿病和血清肌酐。
- 高敏C反应蛋白预测急性肾损伤的最佳阈值对应敏感性76.5%、特异性64.6%。
- 高敏C反应蛋白>6.6 mg/L者急性肾损伤发生率显著更高(P=0.001)。
临床怎么用
- 对动脉瘤性蛛网膜下腔出血患者,入院时可检测血清高敏C反应蛋白以辅助评估急性肾损伤风险。
- 高敏C反应蛋白>6.6 mg/L的患者应加强肾功能监测。
- 抗生素治疗与急性肾损伤风险独立相关,临床用药时需关注肾功能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: High-sensitivity C-reactive protein (hs-CRP) is a well-recognized biomarker of neurologic complications and clinical outcome of stroke patients. However, whether hs-CRP can predict the occurrence of acute kidney injury (AKI) in aneurysmal subarachnoid hemorrhage (aSAH) patients is still unclear. The objective of this study was to assess the feasibility of using serum hs-CRP level to predict the occurrence of AKI in aSAH patients. METHODS: One hundred sixty-four aSAH patients were enrolled into a prospective observational study. AKI was diagnosed using the modified Kidney Disease Improving Global Outcomes (KDIGO) standard. The relationship between serum hs-CRP level at admission and occurrence of AKI was analyzed. RESULTS: AKI occurred in 17 patients (10.4%) in this cohort. Patients with AKI had significantly higher hs-CRP levels than those without. The mortality of the AKI group tends to be higher than that of the non-AKI group, but the difference was not statistically significant (4/17 (23.5%) vs. 13/147 (8.8%), P = 0.081). After adjusting for possible confounding factors including World Federation of Neurosurgical Societies grade, diabetes, and serum creatinine, multivariate analysis revealed that serum hs-CRP level and antibiotic therapy were both significant factors independently associated with AKI following aSAH (serum hs-CRP: OR = 1.2, 95% confidence interval (CI) = 1.1-1.3, P = 0.003; antibiotic therapy: OR = 5.8, 95%CI = 1.6-20.7, P = 0.007). Receiver operating characteristic curve analysis showed that hs-CRP had a sensitivity of 76.5% and a specificity of 64.6% for predicting the development of AKI on the basis of the best thresholds. The post hoc log-rank test revealed that patients having serum hs-CRP level > 6.6 mg/L had a significantly higher AKI rate than patients having serum hs-CRP level ≤ 6.6 mg/L (P = 0.001). CONCLUSIONS: Serum hs-CRP level might be helpful as a predictor for the development of AKI in aSAH patients. Delayed cerebral ischemia occurrence rate and mortality of patients with AKI tend to be higher than those of patients without in this cohort; however, they were not significantly different.
引用
- Yang BH, He Q, Ding CY, et al. High-sensitivity C-reactive protein as a predictive factor of acute kidney injury following aneurysmal subarachnoid hemorrhage: a prospective observational study. Acta Neurochir (Wien). 2019. PMID: 31317264. doi:10.1007/s00701-019-04006-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。